ArticleBMC neurology2025
Association between initial serum cystatin C level and prognosis of aneurysmal subarachnoid hemorrhage.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAneurysmal subarachnoid hemorrhage (aSAH) patients usually suffer poor survival outcome and severe morbidity. Evaluating prognosis of aSAH patients in acute phase is essential for physicians to make suitable treatments strategies. This study was performed to explore the relation between initial serum cystatin C level and outcome of aSAH patients.
methodsThree hundred seven aSAH patients were included. Univariate and multivariate logistic regression were used to analyze the relationship between initial serum cystatin C level with mortality and unfavorable functional outcome of aSAH patients. Receiver operating characteristic curve (ROC) was drawn and area under the ROC curve (AUC) was calculated to evaluate the prognostic value of serum cystatin C in aSAH.
resultsThe incidence of mortality and unfavorable functional outcome in included 307 aSAH patients was 18.2% and 49.2%. Compared with survivors or patients with mRS < 3, non-survivors or those with mRS ≥ 3 had lower GCS and higher WFNS, Hunt-Hess, mFisher score. Serum cystatin C level was also higher in non-survivors or whose mRS ≥ than survivors or whose mRS < 3. Multivariate logistic regression showed serum cystatin C was significantly associated with mortality (p = 0.012) but not unfavorable functional outcome (p = 0.053) of aSAH. The AUC of serum cystatin C for predicting mortality and unfavorable functional outcome of aSAH patients was 0.718 and 0.669, respectively.
conclusionsInitial serum cystatin C level is positively associated with mortality of aSAH patients. Evaluating serum cystatin C level is useful for clinicians to risk the severity of aSAH patients and therefore make personalized treatments regimen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.